Kaplan R, Zhao Y, Tsai J, et al. Preclinical pharmacology, pharmacokinetics, and pharmacodynamics of veligrotug, a full antagonist antibody to the IGF-1 receptor in development for thyroid eye disease. MAbs. 2025;17(1):2585616. doi:10.1080/19420862.2025.2585616
Kaplan R, Zhao Y, Tsai J, et al. Preclinical pharmacology, pharmacokinetics, and pharmacodynamics of veligrotug, a full antagonist antibody to the IGF-1 receptor in development for thyroid eye disease. MAbs. 2025;17(1):2585616. doi:10.1080/19420862.2025.2585616
Kaplan R, Zhao Y, Tsai J, et al. Preclinical pharmacology, pharmacokinetics, and pharmacodynamics of veligrotug, a full antagonist antibody to the IGF-1 receptor in development for thyroid eye disease. MAbs. 2025;17(1):2585616. doi:10.1080/19420862.2025.2585616
Kaplan R, Zhao Y, Tsai J, et al. Preclinical pharmacology, pharmacokinetics, and pharmacodynamics of veligrotug, a full antagonist antibody to the IGF-1 receptor in development for thyroid eye disease. MAbs. 2025;17(1):2585616. doi:10.1080/19420862.2025.2585616